Literature DB >> 2249379

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

S H Sindrup1, K Brøsen, P Bjerring, L Arendt-Nielsen, U Larsen, H R Angelo, L F Gram.   

Abstract

The analgesic efficacy and kinetics of a single oral dose of 75 mg codeine was investigated in 12 extensive metabolizers and 12 poor metabolizers of sparteine in a double-blind, placebo-controlled crossover study. The cosegregation of the O-demethylation of codeine to morphine with the sparteine oxidation polymorphism was confirmed. Hence morphine could not be detected in the plasma of any of the poor metabolizers, whereas detectable morphine plasma levels were found in 10 of 12 extensive metabolizers. Pain thresholds to laser stimuli were determined before drug intake and 90, 150, and 210 minutes after drug intake. Codeine significantly increased the pricking pain thresholds in the extensive metabolizers (p less than 0.05), whereas there were no significant changes in the poor metabolizers. No change in pain thresholds occurred with placebo in any of the two phenotypes. In the extensive metabolizers there was a significant positive correlation between the increase in pain threshold and plasma concentration of codeine. The study supports the hypothesis that morphine formation is essential for achievement of analgesia during codeine treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249379     DOI: 10.1038/clpt.1990.212

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

1.  Pharmacological and toxicological significance of brain cytochromes P450.

Authors:  V Ravindranath
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

Review 2.  [Genetics, pain and analgesia].

Authors:  U Stamer; B Bayerer; F Stüber
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

Review 3.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

4.  SFINX-a drug-drug interaction database designed for clinical decision support systems.

Authors:  Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2009-02-11       Impact factor: 2.953

Review 5.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 6.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

7.  Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.

Authors:  Douglas M McMillan; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

8.  First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo.

Authors:  Kaidi Zhou; Jibran Y Khokhar; Bin Zhao; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2013-04-23       Impact factor: 5.858

9.  A limited number of prescribed drugs account for the great majority of drug-drug interactions.

Authors:  Johan Holm; Birgit Eiermann; Erik Eliasson; Buster Mannheimer
Journal:  Eur J Clin Pharmacol       Date:  2014-09-06       Impact factor: 2.953

Review 10.  Genes associated with addiction: alcoholism, opiate, and cocaine addiction.

Authors:  Mary Jeanne Kreek; David A Nielsen; K Steven LaForge
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.